Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

2.

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav5685. doi: 10.1126/scitranslmed.aav5685.

PMID:
31391322
3.

Primary HIV-1 strains use Nef to downmodulate HLA-E surface expression.

Thans TVS, Akko JI, Niehrs A, Garcia-Beltran WF, Richert L, Stürzel CM, Ford CT, Li H, Ochsenbauer C, Kappes JC, Hahn BH, Kirchhoff F, Martrus G, Sauter D, Altfeld M, Hölzemer A.

J Virol. 2019 Aug 2. pii: JVI.00719-19. doi: 10.1128/JVI.00719-19. [Epub ahead of print]

PMID:
31375574
4.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

5.

Neutrophil extracellular traps prevent HIV infection in the female genital tract.

Barr FD, Ochsenbauer C, Wira CR, Rodriguez-Garcia M.

Mucosal Immunol. 2018 Sep;11(5):1420-1428. doi: 10.1038/s41385-018-0045-0. Epub 2018 Jun 6.

6.

Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses.

Prévost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, Ochsenbauer C, Finzi A.

J Virol. 2018 Jun 13;92(13). pii: e00484-18. doi: 10.1128/JVI.00484-18. Print 2018 Jul 1.

7.

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Bardhi A, Wu Y, Chen W, Li W, Zhu Z, Zheng JH, Wong H, Jeng E, Jones J, Ochsenbauer C, Kappes JC, Dimitrov DS, Ying T, Goldstein H.

J Virol. 2017 Sep 27;91(20). pii: e00937-17. doi: 10.1128/JVI.00937-17. Print 2017 Oct 15.

8.

Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells.

Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR.

Cell Rep. 2017 Jul 25;20(4):984-998. doi: 10.1016/j.celrep.2017.06.087.

9.

Characterization of immune cells and infection by HIV in human ovarian tissues.

Shen Z, Rodriguez-Garcia M, Ochsenbauer C, Wira CR.

Am J Reprod Immunol. 2017 Jul;78(1). doi: 10.1111/aji.12687. Epub 2017 Apr 11.

10.

The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria.

Yoder AC, Guo K, Dillon SM, Phang T, Lee EJ, Harper MS, Helm K, Kappes JC, Ochsenbauer C, McCarter MD, Wilson CC, Santiago ML.

PLoS Pathog. 2017 Feb 27;13(2):e1006226. doi: 10.1371/journal.ppat.1006226. eCollection 2017 Feb.

11.

Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells.

Neidleman JA, Chen JC, Kohgadai N, Müller JA, Laustsen A, Thavachelvam K, Jang KS, Stürzel CM, Jones JJ, Ochsenbauer C, Chitre A, Somsouk M, Garcia MM, Smith JF, Greenblatt RM, Münch J, Jakobsen MR, Giudice LC, Greene WC, Roan NR.

PLoS Pathog. 2017 Feb 16;13(2):e1006163. doi: 10.1371/journal.ppat.1006163. eCollection 2017 Feb.

12.

CD4 regulatory T cells augment HIV-1 expression of polarized M1 and M2 monocyte derived macrophages.

Robinson TO, Zhang M, Ochsenbauer C, Smythies LE, Cron RQ.

Virology. 2017 Apr;504:79-87. doi: 10.1016/j.virol.2017.01.018. Epub 2017 Jan 31.

13.

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.

Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL, Mize GJ, Pollara J, Hladik F, Ochsenbauer C, Denny TN, Warrier R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Ferrari G, Shaw GM, Xia SM, Liao HX, Montefiori DC, Tomaras GD, Haynes BF, McElrath JM.

EBioMedicine. 2016 Dec;14:97-111. doi: 10.1016/j.ebiom.2016.11.024. Epub 2016 Nov 21.

14.

Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV.

Rodriguez-Garcia M, Shen Z, Barr FD, Boesch AW, Ackerman ME, Kappes JC, Ochsenbauer C, Wira CR.

Mucosal Immunol. 2017 Mar;10(2):531-544. doi: 10.1038/mi.2016.72. Epub 2016 Aug 31.

15.

Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys.

Himes JE, Ho C, Nguyen QN, Amos JD, Xu H, Chan C, Chow SC, Ochsenbauer C, Kaidarova Z, Keating SM, Fouda GG, Permar SR.

J Virol. 2016 Sep 12;90(19):8795-808. doi: 10.1128/JVI.00701-16. Print 2016 Oct 1.

16.

Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.

Le Grand R, Dereuddre-Bosquet N, Dispinseri S, Gosse L, Desjardins D, Shen X, Tolazzi M, Ochsenbauer C, Saidi H, Tomaras G, Prague M, Barnett SW, Thiebaut R, Cope A, Scarlatti G, Shattock RJ.

J Virol. 2016 May 12;90(11):5315-5328. doi: 10.1128/JVI.00230-16. Print 2016 Jun 1.

17.

High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis.

Thomas T, Seay K, Zheng JH, Zhang C, Ochsenbauer C, Kappes JC, Goldstein H.

Methods Mol Biol. 2016;1354:221-35. doi: 10.1007/978-1-4939-3046-3_15.

PMID:
26714715
18.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G.

J Clin Invest. 2015 Nov 2;125(11):4077-90. doi: 10.1172/JCI82314. Epub 2015 Sep 28.

19.

Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.

Pollara J, McGuire E, Fouda GG, Rountree W, Eudailey J, Overman RG, Seaton KE, Deal A, Edwards RW, Tegha G, Kamwendo D, Kumwenda J, Nelson JA, Liao HX, Brinkley C, Denny TN, Ochsenbauer C, Ellington S, King CC, Jamieson DJ, van der Horst C, Kourtis AP, Tomaras GD, Ferrari G, Permar SR.

J Virol. 2015 Oct;89(19):9952-61. doi: 10.1128/JVI.01560-15. Epub 2015 Jul 22.

20.

The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Seay K, Khajoueinejad N, Zheng JH, Kiser P, Ochsenbauer C, Kappes JC, Herold B, Goldstein H.

J Virol. 2015 Sep;89(18):9559-70. doi: 10.1128/JVI.01326-15. Epub 2015 Jul 8.

21.

Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.

Alberti MO, Jones JJ, Miglietta R, Ding H, Bakshi RK, Edmonds TG, Kappes JC, Ochsenbauer C.

AIDS Res Hum Retroviruses. 2015 Dec;31(12):1278-96. doi: 10.1089/aid.2015.0074. Epub 2015 Jun 23.

22.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

23.

In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.

Seay K, Church C, Zheng JH, Deneroff K, Ochsenbauer C, Kappes JC, Liu B, Jeng EK, Wong HC, Goldstein H.

J Virol. 2015 Jun;89(12):6264-74. doi: 10.1128/JVI.00563-15. Epub 2015 Apr 1.

24.

Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones.

Miglietta R, Pastori C, Venuti A, Ochsenbauer C, Lopalco L.

J Transl Med. 2014 Dec 13;12:346. doi: 10.1186/s12967-014-0346-3.

25.

Macrophage infection via selective capture of HIV-1-infected CD4+ T cells.

Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ.

Cell Host Microbe. 2014 Dec 10;16(6):711-21. doi: 10.1016/j.chom.2014.10.010. Epub 2014 Nov 20.

26.

Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation.

Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, Cummins NW, Correia C, Meng XW, Tarara JE, Ramirez-Alvarado M, Katzmann DJ, Ochsenbauer C, Kappes JC, Kaufmann SH, Badley AD.

J Cell Biol. 2014 Sep 29;206(7):867-76. doi: 10.1083/jcb.201405051. Epub 2014 Sep 22. Erratum in: J Cell Biol. 2014 Oct 13;207(1):159.

27.

Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Planque SA, Mitsuda Y, Chitsazzadeh V, Gorantla S, Poluektova L, Nishiyama Y, Ochsenbauer C, Morris MK, Sapparapu G, Hanson CV, Massey RJ, Paul S.

AIDS. 2014 Sep 24;28(15):2201-11. doi: 10.1097/QAD.0000000000000392.

28.

Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions.

Patel MV, Ghosh M, Fahey JV, Ochsenbauer C, Rossoll RM, Wira CR.

Am J Reprod Immunol. 2014 Jul;72(1):22-33. doi: 10.1111/aji.12218. Epub 2014 May 8.

29.

Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.

Sarzotti-Kelsoe M, Daniell X, Todd CA, Bilska M, Martelli A, LaBranche C, Perez LG, Ochsenbauer C, Kappes JC, Rountree W, Denny TN, Montefiori DC.

J Immunol Methods. 2014 Jul;409:147-60. doi: 10.1016/j.jim.2014.02.013. Epub 2014 Mar 6.

30.

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC.

J Virol. 2014 Mar;88(5):2489-507. doi: 10.1128/JVI.02853-13. Epub 2013 Dec 18.

31.

Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.

McLinden RJ, Labranche CC, Chenine AL, Polonis VR, Eller MA, Wieczorek L, Ochsenbauer C, Kappes JC, Perfetto S, Montefiori DC, Michael NL, Kim JH.

PLoS One. 2013 Nov 28;8(11):e77756. doi: 10.1371/journal.pone.0077756. eCollection 2013.

32.

Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.

Chenine AL, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, Molnar S, McLinden R, Edmonds T, Hirsch I, O'Connell R, McCutchan FE, Montefiori DC, Ochsenbauer C, Kappes JC, Kim JH, Polonis VR, Tovanabutra S.

PLoS One. 2013 Nov 29;8(11):e76104. doi: 10.1371/journal.pone.0076104. eCollection 2013.

33.

High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.

Duncan CJ, Williams JP, Schiffner T, Gärtner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ.

J Virol. 2014 Feb;88(4):2025-34. doi: 10.1128/JVI.03245-13. Epub 2013 Dec 4.

34.

Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P.

Retrovirology. 2013 Dec 3;10:146. doi: 10.1186/1742-4690-10-146.

35.

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.

Naarding MA, Fernandez N, Kappes JC, Hayes P, Ahmed T, Icyuz M, Edmonds TG, Bergin P, Anzala O, Hanke T, Clark L, Cox JH, Cormier E, Ochsenbauer C, Gilmour J.

J Immunol Methods. 2014 Jul;409:161-73. doi: 10.1016/j.jim.2013.11.021. Epub 2013 Nov 28.

36.

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.

Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13540-5. doi: 10.1073/pnas.1304985110. Epub 2013 Jul 22.

37.

Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy.

Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H.

PLoS One. 2013 May 15;8(5):e63537. doi: 10.1371/journal.pone.0063537. Print 2013.

38.

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis VR, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD.

J Virol. 2013 Jul;87(14):7828-36. doi: 10.1128/JVI.02737-12. Epub 2013 May 8.

39.

Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection.

Rodriguez-Garcia M, Biswas N, Patel MV, Barr FD, Crist SG, Ochsenbauer C, Fahey JV, Wira CR.

PLoS One. 2013 Apr 17;8(4):e62069. doi: 10.1371/journal.pone.0062069. Print 2013.

40.

Phenotypic properties of transmitted founder HIV-1.

Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP Jr, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33. doi: 10.1073/pnas.1304288110. Epub 2013 Mar 29.

41.

Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants.

Fouda GG, Mahlokozera T, Salazar-Gonzalez JF, Salazar MG, Learn G, Kumar SB, Dennison SM, Russell E, Rizzolo K, Jaeger F, Cai F, Vandergrift NA, Gao F, Hahn B, Shaw GM, Ochsenbauer C, Swanstrom R, Meshnick S, Mwapasa V, Kalilani L, Fiscus S, Montefiori D, Haynes B, Kwiek J, Alam SM, Permar SR.

Retrovirology. 2013 Jan 10;10:3. doi: 10.1186/1742-4690-10-3.

42.

HIV-1 expressing the envelopes of transmitted/founder or control/reference viruses have similar infection patterns of CD4 T-cells in human cervical tissue ex vivo.

Merbah M, Arakelyan A, Edmonds T, Ochsenbauer C, Kappes JC, Shattock RJ, Grivel JC, Margolis LB.

PLoS One. 2012;7(12):e50839. doi: 10.1371/journal.pone.0050839. Epub 2012 Dec 6.

43.

Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelope-expressing chimeric virus.

King DF, Siddiqui AA, Buffa V, Fischetti L, Gao Y, Stieh D, McKay PF, Rogers P, Ochsenbauer C, Kappes JC, Arts EJ, Shattock RJ.

J Virol. 2013 Jan;87(2):890-9. doi: 10.1128/JVI.02216-12. Epub 2012 Nov 7.

44.

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW.

PLoS Pathog. 2012;8(5):e1002686. doi: 10.1371/journal.ppat.1002686. Epub 2012 May 31.

45.

Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract.

Lahey T, Ghosh M, Fahey JV, Shen Z, Mukura LR, Song Y, Cu-Uvin S, Mayer KH, Wright PF, Kappes JC, Ochsenbauer C, Wira CR.

PLoS One. 2012;7(6):e38100. doi: 10.1371/journal.pone.0038100. Epub 2012 Jun 4.

46.

Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, Hallahan CW, Wong H, Liu B, You L, Scheid J, Kappes JC, Ochsenbauer C, Nabel GJ, Mascola JR, Connors M.

J Virol. 2012 Aug;86(16):8672-80. doi: 10.1128/JVI.00287-12. Epub 2012 Jun 6.

47.

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH.

J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.

48.

Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr JL, Soderberg KA, Weinhold KJ, Cunningham CK, Denny TN, Crump JA, Cohen MS, McMichael AJ, Haynes BF, Tomaras GD.

J Virol. 2012 Jun;86(12):6835-46. doi: 10.1128/JVI.00437-12. Epub 2012 Apr 18.

49.

The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization.

Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M, Kappes JC, Ngauy V, Marovich M, Michael N, Ochsenbauer C, Montefiori DC, Polonis VR.

PLoS One. 2012;7(4):e29454. doi: 10.1371/journal.pone.0029454. Epub 2012 Apr 11.

50.

Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.

Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC.

J Virol. 2012 Mar;86(5):2715-28. doi: 10.1128/JVI.06157-11. Epub 2011 Dec 21.

Supplemental Content

Loading ...
Support Center